Prevalence,risk factors and outcome of digital gangrene in 2684 lupus patients

Abstract

The aim of the study is to assess the clinical characteristics, risk factors and outcome of patients with systemic lupus erythematosus (SLE) complicated with digital gangrene. In all, 2684 consecutive SLE inpatients admitted to Peking Union Medical College Hospital from December 1997 to August 2007 were studied. Demographic data, clinical features, laboratory findings as well as therapeutic regimens were systematically reviewed and a database was established. Cases with digital gangrene were identified and followed up. 1) Eighteen patients with SLE were complicated with digital gangrene, the average age at event was 33.1 ± 11.8 years and the average disease duration was 99.1 ± 60.1 months. 2) Patients with SLE, with long disease duration (≥4 years), Raynaud’s phenomenon and elevated serum C-reactive protein (CRP) were more likely to develop digital gangrene, P = 0.006, 0.001, and 0.031, respectively, OR = 1.03 (95% CI 1.01, 1.04), 35.76 (95% CI 4.67, 273.83) and 9.93 (95% CI 1.23, 80.30), respectively. 3) Fifteen gangrene patients started prednisone ≥1 mg/kg/d, and 18 were treated with cyclophosphamide, although 8 cases failed and ultimately received digital amputation. Prompt corticosteroid treatment (prednisone ≥1 mg/kg/d started within 3 weeks) decreased the hazard of amputation, P = 0.073, HR = 0.13 (95% CI 0.01, 1.21). Long disease duration, Raynaud’s phenomenon and elevated serum CRP were independent predictive factors for SLE to develop digital gangrene. Early and aggressive corticosteroid treatment prevented gangrene from progression and improved prognosis.

Keywords

C-reactive protein digital gangrene Raynaud’s phenomenon systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

1 da Rocha MC Vilar MJ Freire EA Santiago MB . Arterial occlusion in systemic lupus erythematosus: a good prognostic sign? Clin Rheumatol 2005; 24: 602–605.

2 Kumar N Choudhary N Agarwal G Rizvi Y Kaul B Ahlawat R . Extensive medium-vessel vasculitis with SLE: an unusual association. J Clin Rheumatol 2007; 13: 140–142.

3 Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

4 Vasugi Z Danda D . Systemic lupus erythematosus with antiphospholipid antibody syndrome: a mimic of Buerger's disease. J Postgrad Med 2006; 52: 132–133.

5 Bhatt SP Handa R Gulati GS . Peripheral vascular disease in systemic lupus erythematosus. Lupus 2007; 16: 720–723.

6 Hossny E Hady HA Mabrouk R . Anti-centromere antibodies as a marker of Raynaud's phenomenon in pediatric rheumatologic diseases. Pediatr Allergy Immunol 2000; 11: 250–255.

7 Mitwalli AH Memon NA Abu-Aisha H . Transverse myelitis in a patient with severe lupus nephritis: a case report. Saudi J Kidney Dis Transpl 2002; 13: 492–497.

8 Bruce IN . ‘Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1492–1502.

9 Freire BF da Silva RC Fabro AT dos Santos DC . Is systemic lupus erythematosus a new risk factor for atherosclerosis? Arq Bras Cardiol 2006; 87: 300–306.

10.

10 Nikpour M Urowitz MB Gladman DD . Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31: 329–354 vii–viii.

11.

11 Souza AW Hatta FS Miranda F Sato EI . Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Med J 2005; 123: 137–142.

12.

12 Wajed J Ahmad Y Durrington PN Bruce IN . Prevention of cardiovascular disease in systemic lupus erythematosus–proposed guidelines for risk factor management. Rheumatology (Oxford) 2004; 43: 7–12.

13.

13 Zhang X Tian X Zhang F . Premature atherosclerosis-related central nervous system involvement in two cases of systemic lupus erythematosus. J Clin Rheumatol 2007; 13: 211–212.

14.

14 Best LG Davidson M North KE . Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study. Circulation 2004; 109: 471–475.

15.

15 Von Feldt JM Scalzi LV Cucchiara AJ . Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2220–2227.

16.

16 Sarkissian T Beyene J Feldman B McCrindle B Silverman ED . Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum 2007; 56: 631–638.

17.

17 Svenungsson E Gunnarsson I Fei GZ Lundberg IE Klareskog L Frostegård J . Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533–2540.

18.

18 Abou-Raya A el-Hallous D Fayed H . 8-Isoprostaglandin F2 alpha: a potential index of lipid peroxidation in systemic lupus erythematosus. Clin Invest Med 2004; 27: 306–311.

19.

19 Blankenberg S Stengel D Rupprecht HJ . Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 2003; 44: 1381–1386.

20.

20 Frostegård J . Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005; 25: 1776–1785.

21.

21 Selzer F Sutton-Tyrrell K Fitzgerald SG . Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 151–159.

22.

22 Danesh J Wheeler JG Hirschfield GM . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387–1397.

23.

23 Toloza SM Uribe AG McGwin G . Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947–3957.

24.

24 Oksjoki R Kovanen PT Pentikäinen MO . Role of complement activation in atherosclerosis. Curr Opin Lipidol 2003; 14: 477–482.

25.

25 Danenberg HD Szalai AJ Swaminathan RV . Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108: 512–515.

26.

26 Asherson RA Cervera R Shoenfeld Y . Peripheral vascular occlusions leading to gangrene and amputations in antiphospholipid antibody positive patients. Ann N Y Acad Sci 2007; 1108: 515–529.

27.

27 Asherson RA Cervera R Klumb E . Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum 2008; 38: 124–131.

28.

28 Asherson RA Derksen RH Harris EN . Large vessel occlusion and gangrene in systemic lupus erythematosus and “lupus-like” disease. A report of six cases. J Rheumatol 1986; 13: 740–747.

29.

29 Thiagarajan P . Atherosclerosis, autoimmunity, and systemic lupus erythematosus. Circulation 2001; 104: 1876–1877.

30.

30 Bessant R Duncan R Ambler G . Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum 2006; 55: 892–899.

31.

31 Hörkkö S Olee T Mo L . Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 2001; 103: 941–946.